Aspen acquires Sandoz subsidiary as it seeks to expand in China
The drugmaker is set to take over the Chinese business of Swiss generic pharmaceutical manufacturer Sandoz
Pharmaceutical manufacturer Aspen Pharmacare will acquire Swiss drug maker Sandoz’s Chinese subsidiary for up to €92.6m (R1.9bn) as it seeks to expand its footprint in China, it announced on Monday.
It will also sell Sandoz the European commercial rights to a portfolio of four anaesthetic drugs in a linked deal worth up to €55.5m (R1.1bn). ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.